ARROWHEAD PHARMACEUTICALS, INC. Long-term Line of Credit, Noncurrent
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Long-term Line of Credit, Noncurrent of $141.37 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermLineOfCredit · last filed 2026-08-04
- 2026-06-30: Long-term Line of Credit, Noncurrent $141.37M.
- 2026-03-31: Long-term Line of Credit, Noncurrent $159.64M.
- 2025-12-31: Long-term Line of Credit, Noncurrent $163.11M.
- 2025-09-30: Long-term Line of Credit, Noncurrent $214.88M.
| Period end | Long-term Line of Credit, Noncurrent |
|---|---|
| 2026-06-30 | $141.37M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $159.64M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $163.11M 10-Q · filed 2026-02-05 |
| 2025-09-30 | $214.88M 10-Q · filed 2026-08-04 |
| 2025-06-30 | $200.33M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $208.93M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $407.79M 10-Q · filed 2025-02-10 |
| 2024-09-30 | $393.18M 10-K · filed 2025-11-25 |
| 2023-09-30 | $0.00 10-K · filed 2024-11-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |